Original insights on thrombospondin-1-related antireceptor strategies in cancer

Frontiers in Pharmacology

Volumn 6, Issue OCT, 2015, Pages

  Jeanne, Albin ^a,b,c   Schneider, Christophe ^a,b   Martiny, Laurent ^a,b   Dedieu, Stéphane ^a,b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b CNRS   (France)

^c SATT Nord   (France)

Author keywords

Angiogenesis; Cancer; CD46; CD47; Innovative therapeutic strategies; TSP 1

Indexed keywords

ABT 526; ABT 898; CD36 ANTIGEN; CD47 ANTIGEN; CVX 022; CVX 045; DOXORUBICIN; MONOCLONAL ANTIBODY; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PEPTIDOMIMETIC AGENT; THROMBOSPONDIN 1; TRABECTEDIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL FUNCTION; COLON CARCINOMA; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84949681024     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00252     Document Type: Review

References (166)

1. Baker, L. H., Rowinsky, E. K., Mendelson, D., Humerickhouse, R. A., Knight, R. A., Qian, J., et al. (2008). Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J. Clin. Oncol. 26, 5583-5588. doi: 10.1200/JCO.2008.17.4706
2. Barazi, H. O., Li, Z., Cashel, J. A., Krutzsch, H. C., Annis, D. S., Mosher, D. F., et al. (2002). Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion. J. Biol. Chem. 277, 42859-42866. doi: 10.1074/jbc.M206849200
3. Bauer, P. M., Bauer, E. M., Rogers, N. M., Yao, M., Feijoo-Cuaresma, M., Pilewski, J. M., et al. (2012). Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc. Res. 93, 682-693. doi: 10.1093/cvr/cvr356
4. Baumgartner, J. M., Palmer, B. E., Banerjee, A., and McCarter, M. D. (2008). Role of melanoma secreted thrombospondin-1 on induction of immunosuppressive regulatory T cells through CD47. J. Cancer Mol. 4, 145-152.
5. Belotti, D., Foglieni, C., Resovi, A., Giavazzi, R., and Taraboletti, G. (2011). Targeting angiogenesis with compounds from the extracellular matrix. Int. J. Biochem. Cell Biol. 43, 1674-1685. doi: 10.1016/j.biocel.2011.08.012
6. Bertin, N., Clezardin, P., Kubiak, R., and Frappart, L. (1997). Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res. 57, 396-399.
7. Bi, J., Bai, Z., Ma, X., Song, J., Guo, Y., Zhao, J., et al. (2014). Txr1: an important factor in oxaliplatin resistance in gastric cancer. Med. Oncol. 31:807. doi: 10.1007/s12032-013-0807-1
8. Borsotti, P., Ghilardi, C., Ostano, P., Silini, A., Dossi, R., Pinessi, D., et al. (2015). Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. Pigment Cell Melanoma Res. 28, 73-81. doi: 10.1111/pcmr.12319
9. Bouguermouh, S., Van, V. Q., Martel, J., Gautier, P., Rubio, M., and Sarfati, M. (2008). CD47 expression on T cell is a self-control negative regulator of type 1 immune response. J. Immunol. 180, 8073-8082. doi: 10.4049/jimmunol.180.12.8073
10. Brown, E., Hooper, L., Ho, T., and Gresham, H. (1990). Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J. Cell Biol. 111, 2785-2794. doi: 10.1083/jcb.111.6.2785
11. Brown, L. F., Guidi, A. J., Schnitt, S. J., Van De Water, L., Iruela-Arispe, M. L., Yeo, T. K., et al. (1999). Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5, 1041-1056.
12. Byrne, G. J., Hayden, K. E., McDowell, G., Lang, H., Kirwan, C. C., Tetlow, L., et al. (2007). Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int. J. Oncol. 31, 1127-1132.
13. Calvo, D., Dopazo, J., and Vega, M. A. (1995). The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. Genomics 25, 100-106.
14. Campbell, I. G., Freemont, P. S., Foulkes, W., and Trowsdale, J. (1992). An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 52, 5416-5420.
15. Campbell, N., Greenaway, J., Henkin, J., and Petrik, J. (2011). ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol. Cancer Ther. 10, 1876-1885. doi: 10.1158/1535-7163.MCT-11-0402
16. Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., et al. (2013). Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578-589. doi: 10.1158/2159-8290.CD-12-0476
17. Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., et al. (2009). Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 106, 14016-14021. doi: 10.1073/pnas.0906549106
18. Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., et al. (2011a). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384. doi: 10.1158/0008-5472.CAN-10-2238
19. Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., and Weissman, I. L. (2011b). Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118, 4890-4901. doi: 10.1182/blood-2011-02-338020
20. Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., et al. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713. doi: 10.1016/j.cell.2010.07.044
21. Chao, M. P., Weissman, I. L., and Majeti, R. (2012). The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232. doi: 10.1016/j.coi.2012.01.010
22. Choi, S. H., Tamura, K., Khajuria, R. K., Bhere, D., Nesterenko, I., Lawler, J., et al. (2015). Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol. Ther. 23, 235-243. doi: 10.1038/mt.2014.214
23. Clarke, J. M., and Hurwitz, H. I. (2013). Understanding and targeting resistance to anti-angiogenic therapies. J. Gastrointest. Oncol. 4, 253-263. doi: 10.3978/j.issn.2078-6891.2013.036
24. Clemetson, K. J., Pfueller, S. L., Luscher, E. F., and Jenkins, C. S. (1977). Isolation of the membrane glycoproteins of human blood platelets by lectin affinity chromatography. Biochim. Biophys. Acta 464, 493-508. doi: 10.1016/0005-2736(77)90025-6
25. Clezardin, P., Frappart, L., Clerget, M., Pechoux, C., and Delmas, P. D. (1993). Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. 53, 1421-1430.
26. Colombo, G., Margosio, B., Ragona, L., Neves, M., Bonifacio, S., Annis, D. S., et al. (2010). Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J. Biol. Chem. 285, 8733-8742. doi: 10.1074/jbc.M109.085605
27. Coronella, J., Li, L., Johnson, K., Pirie-Shepherd, S., Roxas, G., and Levin, N. (2009). Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body. Anticancer Res. 29, 2243-2252.
28. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584. doi: 10.1126/science.7521539
29. Dawes, J., Pratt, D. A., Dewar, M. S., and Preston, F. E. (1988). Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb. Haemost. 59, 273-276.
30. Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997). CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717. doi: 10.1083/jcb.138.3.707
31. Demaria, S., and Formenti, S. C. (2012). Role of T lymphocytes in tumor response to radiotherapy. Front. Oncol. 2:95. doi: 10.3389/fonc.2012.00095
32. Di, L. (2015). Strategic approaches to optimizing peptide ADME properties. AAPS J. 17, 134-143.
33. Diao, L., and Meibohm, B. (2013). Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 52, 855-868. doi: 10.1007/s40262-013-0079-0
34. Dossi, R., Frapolli, R., Di Giandomenico, S., Paracchini, L., Bozzi, F., Brich, S., et al. (2015). Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int. J. Cancer 136, 721-729. doi: 10.1002/ijc.29023
35. Ebbinghaus, S., Hussain, M., Tannir, N., Gordon, M., Desai, A. A., Knight, R. A., et al. (2007). Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin. Cancer Res. 13, 6689-6695. doi: 10.1158/1078-0432.CCR-07-1477
36. Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., et al. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. U.S.A. 109, 6656-6661. doi: 10.1073/pnas.1121629109
37. Floquet, N., Dedieu, S., Martiny, L., Dauchez, M., and Perahia, D. (2008). Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study. Arch. Biochem. Biophys. 478, 103-109. doi: 10.1016/j.abb.2008.07.015
38. Foley, J. (2013). Ultimate Antibody Cures Every Type Of Cancer In Clinical Tests. Nature World News. Available at: http://www.natureworldnews.com/articles/1091/20130329/ultimate-antibody-cures-type-cancer-clinical-tests-video.htm.
39. Fujimoto, T.-T., Katsutani, S., Shimomura, T., and Fujimura, K. (2003). Thrombospondin-bound integrin-associated protein (CD47) physically and functionally modifies integrin alphaIIbbeta3 by its extracellular domain. J. Biol. Chem. 278, 26655-26665. doi: 10.1074/jbc.M302194200
40. Gao, A. G., and Frazier, W. A. (1994). Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J. Biol. Chem. 269, 29650-29657.
41. Gietema, J. A., Hoekstra, R., de Vos, F. Y., Uges, D. R., van der Gaast, A., Groen, H. J. M., et al. (2006). A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann. Oncol. 17, 1320-1327. doi: 10.1093/annonc/mdl102
42. Gil-Gil, M. J., Mesia, C., Rey, M., and Bruna, J. (2013). Bevacizumab for the treatment of glioblastoma. Clin. Med. Insights Oncol. 7, 123-135. doi: 10.4137/CMO.S8503
43. Grimbert, P., Bouguermouh, S., Baba, N., Nakajima, T., Allakhverdi, Z., Braun, D., et al. (2006). Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J. Immunol. 177, 3534-3541. doi: 10.4049/jimmunol.177.6.3534
44. Guo, N. H., Krutzsch, H. C., Inman, J. K., Shannon, C. S., and Roberts, D. D. (1997). Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J. Pept. Res. 50, 210-221. doi: 10.1111/j.1399-3011.1997.tb01187.x
45. Han, X., Sterling, H., Chen, Y., Saginario, C., Brown, E. J., Frazier, W. A., et al. (2000). CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J. Biol. Chem. 275, 37984-37992. doi: 10.1074/jbc.M002334200
46. Hatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I., and Barclay, A. N. (2008). Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol. Cell 31, 266-277. doi: 10.1016/j.molcel.2008.05.026
47. Haviv, F., Bradley, M. F., Kalvin, D. M., Schneider, A. J., Davidson, D. J., Majest, S. M., et al. (2005). Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J. Med. Chem. 48, 2838-2846. doi: 10.1021/jm0401560
48. Henkin, J., and Volpert, O. V. (2011). Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin. Ther. Targets 15, 1369-1386. doi: 10.1517/14728222.2011.640319
49. Hirano, K., Kuwasako, T., Nakagawa-Toyama, Y., Janabi, M., Yamashita, S., and Matsuzawa, Y. (2003). Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc. Med. 13, 136-141. doi: 10.1016/S1050-1738(03)00026-4
50. Ho, C. C. M., Guo, N., Sockolosky, J. T., Ring, A. M., Weiskopf, K., özkan, E., et al. (2015). "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein a (SIRPa) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290, 12650-12663. doi: 10.1074/jbc.M115.648220
51. Hoekstra, R., de Vos, F. Y., Eskens, F. A., Gietema, J. A., van der Gaast, A., Groen, H. J. M., et al. (2005). Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol. 23, 5188-5197. doi: 10.1200/JCO.2005.05.013
52. Incardona, F., Lewalle, J. M., Morandi, V., Lambert, S., Legrand, Y., Foidart, J. M., et al. (1995). Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res. 55, 166-173.
53. Isenberg, J. S., Annis, D. S., Pendrak, M. L., Ptaszynska, M., Frazier, W. A., Mosher, D. F., et al. (2009a). Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J. Biol. Chem. 284, 1116-1125. doi: 10.1074/jbc.M804860200
54. Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., and Roberts, D. D. (2009b). Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat. Rev. Cancer 9, 182-194. doi: 10.1038/nrc2561
55. Isenberg, J. S., Shiva, S., and Gladwin, M. (2009c). Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 21, 52-62. doi: 10.1016/j.niox.2009.05.005
56. Isenberg, J. S., Frazier, W. A., and Roberts, D. D. (2008a). Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell. Mol. Life Sci. 65, 728-742. doi: 10.1007/s00018-007-7488-x
57. Isenberg, J. S., Hyodo, F., Ridnour, L. A., Shannon, C. S., Wink, D. A., Krishna, M. C., et al. (2008b). Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia 10, 886-896. doi: 10.1593/neo.08264
58. Isenberg, J. S., Maxhimer, J. B., Hyodo, F., Pendrak, M. L., Ridnour, L. A., DeGraff, W. G., et al. (2008c). Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am. J. Pathol. 173, 1100-1112. doi: 10.2353/ajpath.2008.080237
59. Isenberg, J. S., Romeo, M. J., Yu, C., Yu, C. K., Nghiem, K., Monsale, J., et al. (2008d). Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111, 613-623. doi: 10.1182/blood-2007-06-098392
60. Isenberg, J. S., Jia, Y., Fukuyama, J., Switzer, C. H., Wink, D. A., and Roberts, D. D. (2007). Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem. 282, 15404-15415. doi: 10.1074/jbc.M701638200
61. Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., and Roberts, D. D. (2006). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 281, 26069-26080. doi: 10.1074/jbc.M605040200
62. Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285. doi: 10.1016/j.cell.2009.05.046
63. Jayachandran, A., Anaka, M., Prithviraj, P., Hudson, C., McKeown, S. J., Lo, P.-H., et al. (2014). Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget 5, 5782-5797. doi: 10.18632/oncotarget.2164
64. Jeanne, A., Sick, E., Devy, J., Floquet, N., Belloy, N., Theret, L., et al. (2015). Identification of TAX2 Peptide as a New Unpredicted Anti-Cancer Agent. Oncotarget 5. Available at: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=4025 [accessed July 6, 2015].
65. Kalas, W., Swiderek, E., Switalska, M., Wietrzyk, J., Rak, J., and Strzçdala, L. (2013). Thrombospondin-1 receptor mediates autophagy of RAS-expressing cancer cells and triggers tumour growth inhibition. Anticancer. Res. 33, 1429-1438.
66. Kaur, S., Chang, T., Singh, S. P., Lim, L., Mannan, P., Garfield, S. H., et al. (2014). CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J. Immunol. 193, 3914-3924. doi: 10.4049/jimmunol.1303116
67. Kaur, S., Martin-Manso, G., Pendrak, M. L., Garfield, S. H., Isenberg, J. S., and Roberts, D. D. (2010). Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 285, 38923-38932. doi: 10.1074/jbc.M110.172304
68. Kaur, S., Schwartz, A. L., Miller, T. W., and Roberts, D. D. (2015). CD47-dependent regulation of H2S biosynthesis and signaling in T cells. Methods Enzymol. 555, 145-168. doi: 10.1016/bs.mie.2014.11.023
69. Kazerounian, S., Yee, K. O., and Lawler, J. (2008). Thrombospondins in cancer. Cell. Mol. Life Sci. 65, 700-712. doi: 10.1007/s00018-007-7486-z
70. Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., and Weissman, I. L. (2012). Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538-2545. doi: 10.1038/leu.2012.141
71. Kim, M. J., Lee, J.-C., Lee, J.-J., Kim, S., Lee, S. G., Park, S.-W., et al. (2008). Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol. 29, 28-34. doi: 10.1159/000132568
72. Koonen, D. P., Glatz, J. F. C., Bonen, A., and Luiken, J. J. F. P. (2005). Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta 1736, 163-180. doi: 10.1016/j.bbalip.2005.08.018
73. Kvansakul, M., Adams, J. C., and Hohenester, E. (2004). Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J. 23, 1223-1233. doi: 10.1038/sj.emboj.7600166
74. Latour, S., Tanaka, H., Demeure, C., Mateo, V., Rubio, M., Brown, E. J., et al. (2001). Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-a: down-Regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol. 167, 2547-2554. doi: 10.4049/jimmunol.167.5.2547
75. Lawler, J. W., Slayter, H. S., and Coligan, J. E. (1978). Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem. 253, 8609-8616.
76. Leclair, P., and Lim, C. J. (2014). CD47-independent effects mediated by the TSP-derived 4N1K peptide. PLoS ONE 9:e98358. doi: 10.1371/journal.pone.0098358
77. Lee, T. K.-W., Cheung, V. C.-H., Lu, P., Lau, E. Y. T., Ma, S., Tang, K. H., et al. (2014). Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60, 179-191. doi: 10.1002/hep.27070
78. Lee, Y.-J., Koch, M., Karl, D., Torres-Collado, A. X., Fernando, N. T., Rothrock, C., et al. (2010). Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res. 70, 948-956. doi: 10.1158/0008-5472.CAN-09-3094
79. Levin, N. J., Leedom, T. A., Doppalapudi, V. R., Li, L., Lai, J., Johnson, K., et al. (2007). CVX-045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body that potentiates chemotherapy in preclinical colon cancer models. J. Clin. Oncol. 25, 14011.
80. Li, L., Leedom, T. A., Do, J., Huang, H., Lai, J., Johnson, K., et al. (2011). Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl. Oncol. 4, 249-257. doi: 10.1593/tlo.11136
81. Li, S. S., Liu, Z., Uzunel, M., and Sundqvist, K.-G. (2006). Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood 108, 3112-3120. doi: 10.1182/blood-2006-04-016832
82. Li, Z., Calzada, M. J., Sipes, J. M., Cashel, J. A., Krutzsch, H. C., Annis, D. S., et al. (2002). Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J. Cell Biol. 157, 509-519. doi: 10.1083/jcb.200109098
83. Li, Z., He, L., Wilson, K., and Roberts, D. (2001). Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J. Immunol. 166, 2427-2436. doi: 10.4049/jimmunol.166.4.2427
84. Lih, C.-J., Wei, W., and Cohen, S. N. (2006). Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 20, 2082-2095. doi: 10.1101/gad.1441306
85. Lin, X.-D., Chen, S.-Q., Qi, Y.-L., Zhu, J.-W., Tang, Y., and Lin, J.-Y. (2012). Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J. Surg. Oncol. 106, 94-100. doi: 10.1002/jso.23037
86. Lin, Y., Manning, P. T., Jia, J., Gaut, J. P., Xiao, Z., Capoccia, B. J., et al. (2014). CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model. Transplantation 98, 394-401. doi: 10.1097/TP.0000000000000252
87. Lutz, H. U., and Bogdanova, A. (2013). Mechanisms tagging senescent red blood cells for clearance in healthy humans. Front. Physiol. 4:387. doi: 10.3389/fphys.2013.00387
88. Lyu, T., Jia, N., Wang, J., Yan, X., Yu, Y., Lu, Z., et al. (2013). Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8, 1330-1346. doi: 10.4161/epi.26675
89. Maile, L. A., Capps, B. E., Miller, E. C., Aday, A. W., and Clemmons, D. R. (2008). Integrin-associated protein association with Src homology 2 domain containing tyrosine phosphatase substrate 1 regulates IGF-I signaling in vivo. Diabetes 57, 2637-2643. doi: 10.2337/db08-0326
90. Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299. doi: 10.1016/j.cell.2009.05.045
91. Manna, P. P., and Frazier, W. A. (2004). CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res. 64, 1026-1036. doi: 10.1158/0008-5472.CAN-03-1708
92. Markovic, S. N., Suman, V. J., Rao, R. A., Ingle, J. N., Kaur, J. S., Erickson, L. A., et al. (2007). A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am. J. Clin. Oncol. 30, 303-309. doi: 10.1097/01.coc.0000256104.80089.35
93. Martin, D. D. O., Beauchamp, E., and Berthiaume, L. G. (2011). Post-translational myristoylation: fat matters in cellular life and death. Biochimie 93, 18-31. doi: 10.1016/j.biochi.2010.10.018
94. Martinez-Torres, A.-C., Quiney, C., Attout, T., Boullet, H., Herbi, L., Vela, L., et al. (2015). CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLC?1 activation: evidence from mice and humans. PLoS Med. 12:e1001796. doi: 10.1371/journal.pmed.1001796
95. Mawby, W. J., Holmes, C. H., Anstee, D. J., Spring, F. A., and Tanner, M. J. (1994). Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem. J. 304(Pt 2), 525-530. doi: 10.1042/bj3040525
96. Maxhimer, J. B., Soto-Pantoja, D. R., Ridnour, L. A., Shih, H. B., Degraff, W. G., Tsokos, M., et al. (2009). Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci. Transl. Med. 1:3ra7. doi: 10.1126/scitranslmed.3000139
97. McCracken, M. N., Cha, A. C., and Weissman, I. L. (2015). Molecular pathways: activating t cells after cancer cell phagocytosis from blockade of CD47 "Don't Eat Me" signals. Clin. Cancer Res. 21, 3597-3601. doi: 10.1158/1078-0432.CCR-14-2520
98. McDonald, J. F., Zheleznyak, A., and Frazier, W. A. (2004). Cholesterol-independent interactions with CD47 enhance alphavbeta3 avidity. J. Biol. Chem. 279, 17301-17311. doi: 10.1074/jbc.M312782200
99. Meli, M., Pagano, K., Ragona, L., and Colombo, G. (2014). Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitors. PLoS ONE 9:e97153. doi: 10.1371/journal.pone.0097153
100. Miao, W. M., Seng, W. L., Duquette, M., Lawler, P., Laus, C., and Lawler, J. (2001). Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 61, 7830-7839.
101. Mohandas, N., and Gallagher, P. G. (2008). Red cell membrane: past, present, and future. Blood 112, 3939-3948. doi: 10.1182/blood-2008-07-161166
102. Molckovsky, A., and Siu, L. L. (2008). First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol. 1:20.
103. Monk, B. J., Dalton, H., Benjamin, I., and Tanovic, A. (2012). Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr. Pharm. Des. 18, 3754-3769. doi: 10.2174/138161212802002814
104. Moulton, H. M., and Moulton, J. D. (2010). Morpholinos and their peptide conjugates: rherapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 1798, 2296-2303. doi: 10.1016/j.bbamem.2010.02.012
105. Murphy-Ullrich, J. E., and Sage, E. H. (2014). Revisiting the matricellular concept. Matrix Biol. 37, 1-14. doi: 10.1016/j.matbio.2014.07.005
106. Nathan, F. E., Hernandez, E., Dunton, C. J., Treat, J., Switalska, H. I., Joseph, R. R., et al. (1994). Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73, 2853-2858.
107. Naumov, G. N., Bender, E., Zurakowski, D., Kang, S.-Y., Sampson, D., Flynn, E., et al. (2006). A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst. 98, 316-325. doi: 10.1093/jnci/djj068
108. Nie, S., Lo, A., Wu, J., Zhu, J., Tan, Z., Simeone, D. M., et al. (2014). Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J. Proteome Res. 13, 1873-1884. doi: 10.1021/pr400967x
109. Novelli, E. M., Kato, G. J., Ragni, M. V., Zhang, Y., Hildesheim, M. E., Nouraie, M., et al. (2012). Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am. J. Hematol. 87, 326-330. doi: 10.1002/ajh.22274
110. Ohnishi, H., Kobayashi, H., Okazawa, H., Ohe, Y., Tomizawa, K., Sato, R., et al. (2004). Ectodomain shedding of SHPS-1 and its role in regulation of cell migration. J. Biol. Chem. 279, 27878-27887. doi: 10.1074/jbc.M313085200
111. Oldenborg, P. A., Zheleznyak, A., Fang, Y. F., Lagenaur, C. F., Gresham, H. D., and Lindberg, F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054. doi: 10.1126/science.288.5473.2051
112. Olsson, M., Bruhns, P., Frazier, W. A., Ravetch, J. V., and Oldenborg, P.-A. (2005). Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 105, 3577-3582. doi: 10.1182/blood-2004-08-2980
113. Pagano, K., Torella, R., Foglieni, C., Bugatti, A., Tomaselli, S., Zetta, L., et al. (2012). Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS ONE 7:e36990. doi: 10.1371/journal.pone.0036990
114. Perez-Janices, N., Blanco-Luquin, I., Tuñón, M. T., Barba-Ramos, E., Ibáñez, B., Zazpe-Cenoz, I., et al. (2015). EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget 6, 368-380.
115. Pinessi, D., Ostano, P., Borsotti, P., Bello, E., Guffanti, F., Bizzaro, F., et al. (2015). Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connect. Tissue Res. 56, 355-363. doi: 10.3109/03008207.2015.1045065
116. Pohl, J., Ring, A., Korkmaz, U., Ehehalt, R., and Stremmel, W. (2005). FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol. Biol. Cell 16, 24-31. doi: 10.1091/mbc.E04-07-0616
117. Qian, X., and Tuszynski, G. P. (1996). Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc. Soc. Exp. Biol. Med. 212, 199-207. doi: 10.3181/00379727-212-44008
118. Rader, C. (2014). Chemically programmed antibodies. Trends Biotechnol. 32, 186-197. doi: 10.1016/j.tibtech.2014.02.003
119. Ramanathan, S., Mazzalupo, S., Boitano, S., and Montfort, W. R. (2011). Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 50, 7787-7799. doi: 10.1021/bi201060c
120. Rath, G. M., Schneider, C., Dedieu, S., Rothhut, B., Soula-Rothhut, M., Ghoneim, C., et al. (2006a). The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim. Biophys. Acta 1763, 1125-1134. doi: 10.1016/j.bbamcr.2006.08.001
121. Rath, G. M., Schneider, C., Dedieu, S., Sartelet, H., Morjani, H., Martiny, L., et al. (2006b). Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int. J. Biochem. Cell Biol. 38, 2219-2228. doi: 10.1016/j.biocel.2006.07.004
122. Ren, B., Song, K., Parangi, S., Jin, T., Ye, M., Humphreys, R., et al. (2009). A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res. 69, 3856-3865. doi: 10.1158/0008-5472.CAN-08-2940
123. Ridnour, L. A., Cheng, R. Y. S., Weiss, J. M., Kaur, S., Soto-Pantoja, D. R., Basudhar, D., et al. (2015). NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay. Cancer Res. 75, 2788-2799. doi: 10.1158/0008-5472.CAN-14-3011
124. Riessen, R., Kearney, M., Lawler, J., and Isner, J. M. (1998). Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am. Heart. J. 135, 357-364. doi: 10.1016/S0002-8703(98)70105-X
125. Rivera-Fillat, M. P., Reig, F., Martínez, E. M., and Grau-Oliete, M. R. (2010). Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin. J. Pept. Sci. 16, 315-321. doi: 10.1002/psc.1241
126. Roberts, D. D., Isenberg, J. S., Ridnour, L. A., and Wink, D. A. (2007). Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin. Cancer Res. 13, 795-798. doi: 10.1158/1078-0432.CCR-06-1758
127. Rogers, N. M., Sharifi-Sanjani, M., Csányi, G., Pagano, P. J., and Isenberg, J. S. (2014). Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol. 37, 92-101. doi: 10.1016/j.matbio.2014.01.002
128. Rusk, A., McKeegan, E., Haviv, F., Majest, S., Henkin, J., and Khanna, C. (2006). Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin. Cancer Res. 12, 7444-7455. doi: 10.1158/1078-0432.CCR-06-0109
129. Russell, S., Duquette, M., Liu, J., Drapkin, R., Lawler, J., and Petrik, J. (2015). Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. FASEB J. 29, 576-588. doi: 10.1096/fj.14-261636
130. Sage, E. H., and Bornstein, P. (1991). Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J. Biol. Chem. 266, 14831-14834.
131. Sahora, A. I., Rusk, A. W., Henkin, J., McKeegan, E. M., Shi, Y., and Khanna, C. (2012). Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. J. Vet. Intern. Med. 26, 1169-1176. doi: 10.1111/j.1939-1676.2012.00966.x
132. Sarfati, M., Fortin, G., Raymond, M., and Susin, S. (2008). CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr. Drug Targets 9, 842-850. doi: 10.2174/138945008785909310
133. Saumet, A., Slimane, M. B., Lanotte, M., Lawler, J., and Dubernard, V. (2005). Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood 106, 658-667. doi: 10.1182/blood-2004-09-3585
134. Sick, E., Boukhari, A., Deramaudt, T., Rondé, P., Bucher, B., André, P., et al. (2011). Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway. Glia 59, 308-319. doi: 10.1002/glia.21102
135. Sick, E., Jeanne, A., Schneider, C., Dedieu, S., Takeda, K., and Martiny, L. (2012). CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br. J. Pharmacol. 167, 1415-1430. doi: 10.1111/j.1476-5381.2012.02099.x
136. Silverstein, R. L., and Febbraio, M. (2009). CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal. 2:re3. doi: 10.1126/scisignal.272re3
137. Soto-Pantoja, D. R., Kaur, S., and Roberts, D. D. (2015). CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit. Rev. Biochem. Mol. Biol. 50, 212-230. doi: 10.3109/10409238.2015.1014024
138. Soto-Pantoja, D. R., Miller, T. W., Frazier, W. A., and Roberts, D. D. (2012a). Inhibitory signaling through signal regulatory protein-a is not sufficient to explain the antitumor activities of CD47 antibodies. Proc. Natl. Acad. Sci. U.S.A. 109, E2842-E2842. doi: 10.1073/pnas.1205441109
139. Soto-Pantoja, D. R., Miller, T. W., Pendrak, M. L., DeGraff, W. G., Sullivan, C., Ridnour, L. A., et al. (2012b). CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8, 1628-1642. doi: 10.4161/auto.21562
140. Soto-Pantoja, D. R., Ridnour, L. A., Wink, D. A., and Roberts, D. D. (2013a). Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci. Rep. 3:1038. doi: 10.1038/srep01038
141. Soto-Pantoja, D. R., Stein, E. V., Rogers, N. M., Sharifi-Sanjani, M., Isenberg, J. S., and Roberts, D. D. (2013b). Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin. Ther. Targets 17, 89-103. doi: 10.1517/14728222.2013.733699
142. Soto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., et al. (2014). CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 74, 6771-6783. doi: 10.1158/0008-5472.CAN-14-0037-T
143. Starlinger, P., Moll, H. P., Assinger, A., Nemeth, C., Hoetzenecker, K., Gruenberger, B., et al. (2010). Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J. Thromb. Haemost. 8, 1809-1819. doi: 10.1111/j.1538-7836.2010.03908.x
144. Taraboletti, G., Rusnati, M., Ragona, L., and Colombo, G. (2010). Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1, 662-673. doi: 10.18632/oncotarget.200
145. Toth, A. B., Terauchi, A., Zhang, L. Y., Johnson-Venkatesh, E. M., Larsen, D. J., Sutton, M. A., et al. (2013). Synapse maturation by activity-dependent ectodomain shedding of SIRPa. Nat. Neurosci. 16, 1417-1425. doi: 10.1038/nn.3516
146. Tsai, R. K., and Discher, D. E. (2008). Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180, 989-1003. doi: 10.1083/jcb.200708043
147. Tseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., et al. (2013). Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. U.S.A. 110, 11103-11108. doi: 10.1073/pnas.1305569110
148. Tulasne, D., Judd, B. A., Johansen, M., Asazuma, N., Best, D., Brown, E. J., et al. (2001). C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chain-associated signaling pathway and by agglutination. Blood 98, 3346-3352. doi: 10.1182/blood.V98.12.3346
149. Tuszynski, G., Smith, M., Rothman, V., Capuzzi, D., Joseph, R., Katz, J., et al. (1992). Thrombospondin levels in patients with malignancy. Thromb. Haemost. 67, 607-611.
150. van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L., and Griffioen, A. W. (2015). The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 67, 441-461. doi: 10.1124/pr.114.010215
151. Vernon-Wilson, E. F., Kee, W. J., Willis, A. C., Barclay, A. N., Simmons, D. L., and Brown, M. H. (2000). CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur. J. Immunol. 30, 2130-2137.
152. Wang, W., Zhang, E., and Lin, C. (2015). MicroRNAs in tumor angiogenesis. Life Sci. 136, 28-35. doi: 10.1016/j.lfs.2015.06.025
153. Watnick, R. S., Rodriguez, R. K., Wang, S., Blois, A. L., Rangarajan, A., Ince, T., et al. (2015). Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene 34, 2823-2835. doi: 10.1038/onc.2014.228
154. Weng, T.-Y., Huang, S.-S., Yen, M.-C., Lin, C.-C., Chen, Y.-L., Lin, C.-M., et al. (2014). A novel cancer therapeutic using thrombospondin 1 in dendritic cells. Mol. Ther. 22, 292-302. doi: 10.1038/mt.2013.236
155. Williams, S. (2012). One Drug to Shrink All Tumors. Available at: http://news.sciencemag.org/health/2012/03/one-drug-shrink-all-tumors?ref=hp
156. Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., et al. (2012a). The CD47-signal regulatory protein alpha (SIRPalpha) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 6662-6667. doi: 10.1073/pnas.1121623109
157. Willingham, S. B., Volkmer, J.-P., Weiskopf, K., Ring, A. M., and Weissman, I. L. (2012b). Reply to soto-pantoja et al. and Zhao et al.: targeting CD47 on human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 109, E2844-E2845. doi: 10.1073/pnas.1209743109
158. Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., et al. (2015). A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27, 397-408. doi: 10.1016/j.ccell.2015.02.005
159. Xu, J.-F., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., et al. (2015). Cd47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models. Oncotarget 5. Available at: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=4282 [accessed July 8, 2015].
160. Xu, W., Kaneko, F. T., Zheng, S., Comhair, S. A. A., Janocha, A. J., Goggans, T., et al. (2004). Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 18, 1746-1748. doi: 10.1096/fj.04-2317fje
161. Yao, M., Rogers, N. M., Csányi, G., Rodriguez, A. I., Ross, M. A., St. Croix, C., et al. (2014). Thrombospondin-1 activation of signal-regulatory protein-a stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J. Am. Soc. Nephrol. 25, 1171-1186. doi: 10.1681/ASN.2013040433
162. Zhang, X., Galardi, E., Duquette, M., Lawler, J., and Parangi, S. (2005). Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin. Cancer Res. 11, 5622-5630. doi: 10.1158/1078-0432.CCR-05-0459
163. Zhang, X., Kazerounian, S., Duquette, M., Perruzzi, C., Nagy, J. A., Dvorak, H. F., et al. (2009). Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 23, 3368-3376. doi: 10.1096/fj.09-131649
164. Zhao, X. W., Matlung, H. L., Kuijpers, T. W., and van den Berg, T. K. (2012). On the mechanism of CD47 targeting in cancer. Proc. Natl. Acad. Sci. U.S.A. 109, E2843-E2843. doi: 10.1073/pnas.1209265109
165. Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., et al. (2011). CD47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. U.S.A. 108, 18342-18347. doi: 10.1073/pnas.1106550108
166. Zheng, Y., Zou, F., Wang, J., Yin, G., Le, V., Fei, Z., et al. (2015). Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein. J. Biol. Chem. 290, 8975-8986. doi: 10.1074/jbc.M114.624965